An Allergan psychiatric drug failed late-stage depression studies — but AbbVie is going for approval anyway
Cariprazine, the Allergan-turned-AbbVie drug for bipolar depression and schizophrenia, had a rocky road through clinical trials before its approvals. And as AbbVie attempts to further expand into major depressive disorder, it’s facing similar challenges.
Early Friday morning, AbbVie reported largely negative data in two Phase III studies evaluating cariprazine as an adjunct in adults who responded poorly to previous depression treatment. Despite the misses, the pharma intends to submit for a supplemental NDA in MDD using the “totality” of data, as one of these studies showed a positive signal. An earlier Phase II/III trial also proved positive, AbbVie said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.